142 related articles for article (PubMed ID: 31109870)
1. High-dose-rate brachytherapy as monotherapy for prostate cancer: The impact of cellular repair and source decay.
Tien CJ; Carlson DJ; Nath R; Chen ZJ
Brachytherapy; 2019; 18(5):701-710. PubMed ID: 31109870
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of incomplete repair parameters for rat spinal cord: the feasibility of large doses per fraction in PDR and HDR brachytherapy.
Pop LA; Millar WT; Visser AG; van der Kogel AJ
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):215-26. PubMed ID: 11516872
[TBL] [Abstract][Full Text] [Related]
3. Radiobiological evaluation of the stepping-source effect in single-fraction monotherapy high-dose-rate prostate brachytherapy.
Tien CJ; Chen Z
Brachytherapy; 2023; 22(5):593-606. PubMed ID: 37263898
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
5. The optimal fraction size in high-dose-rate brachytherapy: dependency on tissue repair kinetics and low-dose rate.
Sminia P; Schneider CJ; Fowler JF
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):844-9. PubMed ID: 11849810
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different fractionation schedules toward a single fraction in high-dose-rate brachytherapy as monotherapy for low-risk prostate cancer using 3-dimensional radiobiological models.
Mavroidis P; Milickovic N; Cruz WF; Tselis N; Karabis A; Stathakis S; Papanikolaou N; Zamboglou N; Baltas D
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):216-23. PubMed ID: 24331667
[TBL] [Abstract][Full Text] [Related]
7. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
King CR; DiPetrillo TA; Wazer DE
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
[TBL] [Abstract][Full Text] [Related]
8. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
[TBL] [Abstract][Full Text] [Related]
9. Analysis of a large number of clinical studies for breast cancer radiotherapy: estimation of radiobiological parameters for treatment planning.
Guerrero M; Li XA
Phys Med Biol; 2003 Oct; 48(20):3307-26. PubMed ID: 14620060
[TBL] [Abstract][Full Text] [Related]
10. Impact of tumor repopulation on radiotherapy planning.
Wang JZ; Li XA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
[TBL] [Abstract][Full Text] [Related]
11. A radiobiological investigation on dose and dose rate for permanent implant brachytherapy of breast using 125I or 103Pd sources.
Baltas D; Lymperopoulou G; Löffler E; Mavroidis P
Med Phys; 2010 Jun; 37(6):2572-86. PubMed ID: 20632569
[TBL] [Abstract][Full Text] [Related]
12. The impact of cobalt-60 source age on biologically effective dose in high-dose functional Gamma Knife radiosurgery.
Kann BH; Yu JB; Stahl JM; Bond JE; Loiselle C; Chiang VL; Bindra RS; Gerrard JL; Carlson DJ
J Neurosurg; 2016 Dec; 125(Suppl 1):154-159. PubMed ID: 27903196
[TBL] [Abstract][Full Text] [Related]
13. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate.
Okamoto M; Ishikawa H; Ebara T; Kato H; Tamaki T; Akimoto T; Ito K; Miyakubo M; Yamamoto T; Suzuki K; Takahashi T; Nakano T
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e211-7. PubMed ID: 21620579
[TBL] [Abstract][Full Text] [Related]
14. The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer.
Lindsay PE; Moiseenko VV; Van Dyk J; Battista JJ
Phys Med Biol; 2003 Feb; 48(4):507-22. PubMed ID: 12630745
[TBL] [Abstract][Full Text] [Related]
15. BEDVH-A method for evaluating biologically effective dose volume histograms: application to eye plaque brachytherapy implants.
Gagne NL; Leonard KL; Huber KE; Mignano JE; Duker JS; Laver NV; Rivard MJ
Med Phys; 2012 Feb; 39(2):976-83. PubMed ID: 22320806
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations.
Li XA; Wang JZ; Stewart RD; DiBiase SJ
Phys Med Biol; 2003 Sep; 48(17):2753-65. PubMed ID: 14516099
[TBL] [Abstract][Full Text] [Related]
17. How low is the alpha/beta ratio for prostate cancer?
Wang JZ; Guerrero M; Li XA
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):194-203. PubMed ID: 12504054
[TBL] [Abstract][Full Text] [Related]
18. Calculated and simulated effects of heterogeneous dose distributions in radiotherapy using the dose volume inhomogeneity corrected biological equivalent dose formula with special reference to prostate cancer.
Lennernäs B; Albertsson P; Edgren M; Nilsson S
Oncol Rep; 2007 Nov; 18(5):1299-303. PubMed ID: 17914588
[TBL] [Abstract][Full Text] [Related]
19. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report.
Mate TP; Gottesman JE; Hatton J; Gribble M; Van Hollebeke L
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):525-33. PubMed ID: 9635698
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.
Yoshioka Y; Yoshida K; Yamazaki H; Nonomura N; Ogawa K
J Radiat Res; 2013 Sep; 54(5):781-8. PubMed ID: 23543798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
